Last reviewed · How we verify
Boostrix IPV infant acellular Pertussis
Boostrix IPV infant acellular Pertussis is a Biologic drug developed by London School of Hygiene and Tropical Medicine. It is currently FDA-approved.
At a glance
| Generic name | Boostrix IPV infant acellular Pertussis |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) (PHASE3)
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers (PHASE4)
- Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants (PHASE3)
- Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines (PHASE4)
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants (PHASE2)
- Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine (PHASE1)
- Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boostrix IPV infant acellular Pertussis CI brief — competitive landscape report
- Boostrix IPV infant acellular Pertussis updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about Boostrix IPV infant acellular Pertussis
What is Boostrix IPV infant acellular Pertussis?
Boostrix IPV infant acellular Pertussis is a Biologic drug developed by London School of Hygiene and Tropical Medicine.
Who makes Boostrix IPV infant acellular Pertussis?
Boostrix IPV infant acellular Pertussis is developed and marketed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).
What development phase is Boostrix IPV infant acellular Pertussis in?
Boostrix IPV infant acellular Pertussis is FDA-approved (marketed).